The new pathophysiology of coronary artery disease

American Journal of Cardiology

Volumn 82, Issue 10 B, 1998, Pages

  Castelli, William P ^a  

^a Framingham Cardiovascular Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIET; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0032415718     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00729-2     Document Type: Conference Paper

References (26)

1. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
2. Roberts W.C. Qualitative and quantitative comparison of amounts of narrowing by atherosclerotic plaques in the major epicardial coronary arteries at necropsy in sudden coronary death, transmural acute myocardial infarction, transmural healed myocardial infarction and unstable angina pectoris. Am J Cardiol. 64:1989;324-328.
3. Davies M.J. Pathology of coronary atherosclerosis. Alexander R.W., Schlant R.C. Hurst's The Heart, Arteries and Veins. 9th ed. 1998;1161-1175 McGraw-Hill, New York.
4. Ross R. Factors influencing atherogenesis. Alexander R.W., Schlant R.C. Hurst's The Heart, Arteries and Veins. 9th ed. 1998;1139-1159 McGraw-Hill, New York.
5. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
6. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganx P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
7. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
8. Mansur A.P., Amires J.A.R., Cramelli B., Serrano C.V. Jr, Maranhao R., Pileggi F. Effect of cholesterol lowering therapy on positive exercise testing in patients with hypercholesterolemia and normal coronary angiograms. Circulation. 96:1997;I-762.
9. Corretti M.C., Plotnick G.D., Vogel R.A. Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol. 268:1995;H1397-H1404.
10. Vogel R.A., Corretti M.C., Plotnick G.D. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 79:1997;350-354.
11. Plotnick G.D., Corretti M.C., Vogel R.A. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 278:1997;1682-1686.
12. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
13. Castelli W. Cholesterol and lipids in the risk of coronary artery disease the Framingham Heart Study . Can J Cardiol. 4:(suppl A):1988;5A-10A.
14. Castelli W.P., Abbott R.D., McNamara P.M. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 67:1983;730-734.
15. Stampfer M.J., Scacks F.M., Salmini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med. 325:1991;373-381.
16. Kinosian B., Glick H., Garland G. Cholesterol and coronary heart disease predicting risks by levels and ratios . Ann Intern Med. 121:1994;641-647.
17. Hokanson J.E., Austin M.A. Triglyceride is a risk factor of coronary disease in men and women. A meta analysis of population based on prospective studies. Circulation. 88:1993;I.
18. Reaven G.M. Banting Lecture 1988. Role of insulin resistance to human disease. 1988. Nutrition. 65:1997;64.
19. Kaplan N.M. The deadly quartet and the insulin resistance syndrome an historical overview . Hypertens Res. 19:(suppl 1):1996;S9-S11.
20. Williams R.R., Hunt S.C., Hopkins P.N., Stults B.M., Wu L.L., Hasstedt S.J., Barlow G.K., Stephenson S.H., Lalouel J.M., Kuida H. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 259:1988;3579-3586.
21. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 81:(suppl):1998;18B-25B.
22. Pedersen T.R., Kjekshus J., Olsson A.G., Cook T.J. 4S results support AHA guidelines to reduce LDL-cholesterol to less than 100 mg/dL in patients with CHD. Circulation. 96:1997;I-717.
23. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
24. Gould K.L., Martucci J.P., Golberg D.I., Hess M.J., Edens R.P., Latifi R., Dudrick S.J. Short term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease a potential noninvasive marker of healing coronary endothelium . Circulation. 89:1994;1530-1538.
25. Andrews T.C., Raby K., Barry J., Naimi C.L., Allred E., Ganz P., Selwyn A.P. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 95:1997;324-328.
26. Castelli W.P., Garrison R.J., Wilson P.W.F., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels the Framingham Study . JAMA. 256:1986;2835-2838.